Requip

Requip is a non-ergoline dopamine agonist, manufactured by GlaxoSmithKline. It is used in the treatment of Parkinson's disease, and is also one of two medications in the United States with an FDA-approved indication for the treatment of restless legs syndrome (the other being Pramipexole). .
[Wikipedia].

Medicinal name:
  • Ropinirole 4 MG Oral Tablet [Requip]
  • Ropinirole 0.5 MG Oral Tablet [Requip]
  • 24 HR ropinirole 12 MG Extended Release Oral Tablet [Requip]
  • Ropinirole 1 MG Oral Tablet [Requip]
  • Ropinirole 2 MG Oral Tablet [Requip]
  • Ropinirole 5 MG Oral Tablet [Requip]
  • 24 HR ropinirole 4 MG Extended Release Oral Tablet [Requip]
  • 24 HR ropinirole 6 MG Extended Release Oral Tablet [Requip]
  • Ropinirole 0.25 MG Oral Tablet [Requip]
  • Ropinirole 3 MG Oral Tablet [Requip]
  • 24 HR ropinirole 2 MG Extended Release Oral Tablet [Requip]
  • 24 HR ropinirole 8 MG Extended Release Oral Tablet [Requip]

Requip - Pharmacology:

Requip binds the dopamine receptors D3 and D2. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

Requip mini report

Requip NDA
NDA - A product marketed under an approved New Drug Application
Requip TABLET, FILM COATED
TABLET, FILM COATED
Requip TABLET, FILM COATED, EXTENDED RELEASE
TABLET, FILM COATED, EXTENDED RELEASE
Requip HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Requip global name
ropinirole
Requip global name
ropinirole hydrochloride
Start - Stop data
START DATA:
1997-Oct-01
Start - Stop data
STOP DATA
not occurred

Requip Interactions

P 450 Interaction:    In vitro metabolism studies showed that CYP1A2 was the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for substrates or inhibitors of this enzyme when coadministered with ropinirole to alter its clearance. Therefore, if therapy with a drug known to be a potent inhibitor of CYP1A2 is stopped or started during treatment with Requip , adjustment of the Requip dose may be required.

L-dopa:   Co-administration of carbidopa + L-dopa (Sinemet® 10/100 mg b.i.d.) with ropinirole (2.0 mg t.i.d.) had no effect on the steady-state pharmacokinetics of ropinirole (n=28 patients). Oral administration of Requip 2.0 mg t.i.d. increased mean steady state C max of L-dopa by 20% but its AUC was unaffected (n=23 patients).

Digoxin:   Co-administration of Requip (2.0 mg t.i.d.) with digoxin (0.125-0.25 mg q.d.) did not alter the steady-state pharmacokinetics of digoxin in 10 patients.

Theophylline:    Administration of theophylline (300 mg b.i.d., a substrate of CYP1A2) did not alter the steady-state pharmacokinetics of ropinirole (2 mg t.i.d.) in 12 patients with Parkinsons disease. Requip (2 mg t.i.d.) did not alter the pharmacokinetics of theophylline (5 mg/kg i.v.) in 12 patients with Parkinsons disease.

Ciprofloxacin:   Co-administration of ciprofloxacin (500 mg b.i.d.), an inhibitor of CYP1A2, with ropinirole (2 mg t.i.d.) increased ropinirole AUC by 84% on average, and C max by 60% (n=12 patients).

Estrogens:   Population pharmacokinetic analysis revealed that estrogens (mainly ethinylestradiol: intake 0.6-3 mg over 4-month to 23-year period) reduced the oral clearance of ropinirole by 36% in 16 patients. Dosage adjustment may not be needed for Requip in patients on estrogen therapy because patients must be carefully titrated with ropinirole to tolerance or adequate effect. However, if estrogen therapy is stopped or started during treatment with Requip , then adjustment of the Requip (ropinirole hydrochloride) dose may be required.

Dopamine Antagonists:   Since ropinirole is a dopamine agonist, it is possible that dopamine antagonists, such as neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of Requip . Patients with major psychotic disorders, treated with neuroleptics, should only be treated with dopamine agonists if the potential benefits outweigh the risks.

Population analysis showed that commonly administered drugs, e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, and anticholinergics did not affect the oral clearance of ropinirole.

Requip Contraindications

Requip is contraindicated for patients known to have hypersensitivity to the product.

Manufacturers name:

  • GlaxoSmithKline LLC
  • Bryant Ranch Prepack
  • Physicians Total Care, Inc
  • PD-Rx Pharmaceuticals, Inc

Generic name, Overdose, Half Life Requip, Food Interactions, Chemical, etc..

Requip see also FDA report Saw Palmetto

General health

Chemical structure:
N O N H H H H H H H H H H H H H H H H H H H H H H H H C16H24N2O 2D chemical structure C16H24N2O SVG | 2D structure Ropinirole | Oxymetazoline | N-Cyclohexyl-N'-(Propyl)Phenyl Urea | C16H24N2O chemical names, chemical properties, classification C16H24N2O